Know Cancer

or
forgot password

Preclinical Evaluation of Novel CD33-Targeting Therapeutics for Treatment of Acute Myeloid Leukemia (AML)


N/A
N/A
30 Years
Open (Enrolling)
Both
Leukemia

Thank you

Trial Information

Preclinical Evaluation of Novel CD33-Targeting Therapeutics for Treatment of Acute Myeloid Leukemia (AML)


OBJECTIVES:

- To determine, in vitro, the cytotoxic activity of novel CD33-targeting immunoconjugate
agents in cell samples from patients with acute myeloid leukemia (AML).

- To define the characteristics of AML cells responding to or resisting these agents.

OUTLINE: Cell samples are thawed and used for in vitro studies to determine the cytotoxic
activity of novel CD33-targeting immunoconjugate agents, including gemtuzumab ozogamicin,
for genotyping characterization by flow cytometry-based assays and/or western blot, and
colony-forming cell assays.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Diagnosis of acute myeloid leukemia

- Cryopreserved samples available

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Not specified

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Activity of novel CD33-targeting immunoconjugate agents

Safety Issue:

No

Principal Investigator

Soheil Meshinchi, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Fred Hutchinson Cancer Research Center

Authority:

United States: Federal Government

Study ID:

CDR0000675767

NCT ID:

NCT01150058

Start Date:

November 2010

Completion Date:

Related Keywords:

  • Leukemia
  • adult acute myeloid leukemia with 11q23 (MLL) abnormalities
  • adult acute myeloid leukemia with del(5q)
  • adult acute myeloid leukemia with inv(16)(p13;q22)
  • adult acute myeloid leukemia with t(15;17)(q22;q12)
  • adult acute myeloid leukemia with t(16;16)(p13;q22)
  • adult acute myeloid leukemia with t(8;21)(q22;q22)
  • childhood acute myeloid leukemia/other myeloid malignancies
  • adult acute myeloid leukemia
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location